Current status of SRC inhibitors in solid tumor malignancies

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• The Src tyrosine kinase is implicated in various cancers.
• Several Src-targeting agents are under clinical investigation.
• Understanding Src's role is crucial for cancer therapy.

Purpose of the Study:

• To review Src structure, function, and its role in cancer development.
• To analyze preclinical and clinical data of Src inhibitors.
• To highlight ongoing clinical trials and novel therapeutic strategies.

Main Methods:

• Literature review of Src in cancer using PubMed.
• Analysis of Src inhibitors from oncology meeting abstracts (3 years).
• Comprehensive review of clinical trials on ClinicalTrials.gov.

Main Results:

• Src inhibitors show promise but limited monotherapy activity in unselected solid tumors.
• Established efficacy in hematologic malignancies.
• Focus on solid tumors and biomarker-driven trials is increasing.
• New investigational Src-targeting agents are being developed.

Conclusions:

• Src inhibitors require further investigation in solid tumors.
• Combination therapies and biomarker-selected patient populations are key areas for future trials.
• Targeting Src remains a significant area of cancer research.